146 related articles for article (PubMed ID: 30572204)
21. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
Elliot E; Amara A; Jackson A; Moyle G; Else L; Khoo S; Back D; Owen A; Boffito M
J Antimicrob Chemother; 2016 Apr; 71(4):1031-6. PubMed ID: 26679246
[TBL] [Abstract][Full Text] [Related]
22. Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum.
Burger D; Krens S; Robijns K; Aarnoutse R; Brüggemann R; Touw D
Ther Drug Monit; 2014 Dec; 36(6):824-7. PubMed ID: 24819970
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of ultra performance liquid chromatography-tandem mass spectrometry method for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form.
Veerareddy V; Dodda S; Gangarapu K
Eur J Mass Spectrom (Chichester); 2021 Dec; 27(6):249-255. PubMed ID: 34851199
[TBL] [Abstract][Full Text] [Related]
24. A sensitive and selective liquid chromatographic tandem mass spectrometric assay for simultaneous quantification of novel trioxane antimalarials in different biomatrices using sample-pooling approach for high throughput pharmacokinetic studies.
Singh RP; Sabarinath S; Singh SK; Gupta RC
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 864(1-2):52-60. PubMed ID: 18316253
[TBL] [Abstract][Full Text] [Related]
25. Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Liang F; Terry AV; Bartlett MG
Biomed Chromatogr; 2012 Nov; 26(11):1325-32. PubMed ID: 22259043
[TBL] [Abstract][Full Text] [Related]
26. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
Blakney AK; Jiang Y; Whittington D; Woodrow KA
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():110-8. PubMed ID: 27236000
[TBL] [Abstract][Full Text] [Related]
28. High-throughput quantification of 8 antihypertensive drugs and active metabolites in human plasma using UPLC-MS/MS.
van der Nagel BCH; Versmissen J; Bahmany S; van Gelder T; Koch BCP
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():367-373. PubMed ID: 28666228
[TBL] [Abstract][Full Text] [Related]
29. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
Nguyen B; Foisy MM; Hughes CA
Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
[No Abstract] [Full Text] [Related]
31. Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots.
Akinloye A; Eniayewu O; Adeagbo B; Bolaji O; Olagunju A
Ther Drug Monit; 2022 Jun; 44(3):430-437. PubMed ID: 34629444
[TBL] [Abstract][Full Text] [Related]
32. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues.
Ramöller IK; Abbate MTA; Vora LK; Hutton ARJ; Peng K; Volpe-Zanutto F; Tekko IA; Moffatt K; Paredes AJ; McCarthy HO; Donnelly RF
J Pharm Biomed Anal; 2022 May; 213():114698. PubMed ID: 35259714
[TBL] [Abstract][Full Text] [Related]
33. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
Yamada E; Takagi R; Moro H; Sudo K; Kato S
PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
[TBL] [Abstract][Full Text] [Related]
34. Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
Denault JS; Cabot JF; Langlois H; Marcotte S; Sheehan NL
Antivir Ther; 2019; 24(1):73-76. PubMed ID: 30353885
[TBL] [Abstract][Full Text] [Related]
35. Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
Wu L; Ye Z; Liu H; Guo H; Lin J; Zheng L; Chu N; Liu X
J Pharm Biomed Anal; 2020 Feb; 180():113076. PubMed ID: 31896523
[TBL] [Abstract][Full Text] [Related]
36. Dolutegravir for the treatment of adult patients with HIV-1 infection.
Wu G; Abraham T; Saad N
Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
[TBL] [Abstract][Full Text] [Related]
37. Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS.
van Seyen M; de Graaff Teulen MJA; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1110-1111():15-24. PubMed ID: 30776611
[TBL] [Abstract][Full Text] [Related]
38. A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma.
Jolibois J; Schmitt A; Royer B
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Nov; 1132():121844. PubMed ID: 31678788
[TBL] [Abstract][Full Text] [Related]
39. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.
D'Avolio A; Siccardi M; Sciandra M; Baietto L; Bonora S; Trentini L; Di Perri G
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(2):234-40. PubMed ID: 17964231
[TBL] [Abstract][Full Text] [Related]
40. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
